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Background: In HER2þ breast cancer (BC) patients (pts) the pathological complete
response (pCR) is associated with improved survival. With regimens based on the com-
bination of trastuzumab (T), pertuzumab (P) and chemotherapy, pCR rates are slightly
over 48%.We conducted a retrospective analysis on HER2þ BC pts to describe the out-
comes of neoadjuvant combination of PþT and chemotherapy in the real-life setting.
Methods:Our cohort included 64 pts treated between Sept 2015 andMar 2018 in 15
Italian Cancer Centers. Treatment outcomes were analyzed in terms of pCR (defined as
ypT0/Tis, ypN0i-) and toxicities, recorded according to National Cancer Institute
Common Toxicity Criteria. Statistical analysis was performed with T di Student test
and v2 test.
Results:Overall, in the 55 evaluable pts median age was 50 (range 28-77) and 29 pts
(53%) were pre-menopausal. 24 pts (45%) were ER-/PgR-, 12 (21%) ERþ/PgR-, 16
(29%) ERþ/PgRþ, median ki67 was 40. 9% of pts were cT1, 73% cT2, 13% cT3 and
5% cT4; 42 pts (76%) were cNþ. All pts received 4 cycles of T (8mg/kg loading dose,
followed by 6mg/kg every 3 weeks) and P (loading dose 840mg, followed by 420mg
every 3 weeks). In 42 pts TþP were administered with docetaxel (75mg/mq every 3
weeks), in 8 pts with paclitaxel (80mg/mq) and 5 pts received docetaxel and carbopla-
tin (AUC5). In 13 pts also 3 cycles of anthracyclines, according to the FEC scheme, were
administered. A pCR was achieved in 29 pts (53%). No significant associations were
found between pCR and baseline characteristics or treatments schedule. Seven out of
55 (13%) pts reported G3-G4 toxicities (5 pts neutropenia G3-G4, 1 pt vomiting G3,
1 pt diarrhoea G3, 1 pt anemia G3). Three out of 4 pts treated with docetaxel, carbopla-
tin and PþT reported G3/G4 toxicities. A significant association was found between
chemotherapy schedule and toxicities (p¼ 0.004).
Conclusions: The association of PþTþchemotherapy improved pCR rate in HER2þ
BC pts treated in the real-life setting. Our results showed that the selection of chemo-
therapy that will be associated with the dual blockade of HER2 is of paramount impor-
tance in order to avoid severe toxicities and increase the compliance with treatment.
Legal entity responsible for the study:Department of Oncology, Belcolle Hospital.
Funding:Has not received any funding.
Disclosure: All authors have declared no conflicts of interest.
208P Real-world comparison of the impact of adjuvant capecitabine in
women with high-risk triple-negative breast cancer after neoadjuvant
chemotherapy
M.T.S. Vilbert1, M.P. Corassa2, R.R. Saleh3, R.L. Coelho2, M.R.D.J. Teixeira1, E. Amir3
1Clinical Oncology, A. C. Camargo Cancer Center, Sao Paulo, Brazil, 2Medical Oncology,
A. C. Camargo Cancer Center, Sao Paulo, Brazil, 3Medical Oncology and Hematology,
Princess Margaret Cancer Center, Toronto, ON, Canada
Background: Adjuvant capecitabine (adjC) is recommended for patients with triple-
negative breast cancer (TNBC) and poor response to neoadjuvant chemotherapy.
Despite evidence of benefit, this therapy is not available in situations of limited resour-
ces, such as in the Brazilian public health system.
Methods: A retrospective observational cohort study was conducted in Princess
Margaret (PM) Cancer Centre in Toronto, Canada, and in A.C.Camargo Cancer
Center (AC) in S~ao Paulo, Brazil. Patients with TNBCwho had completed neoadjuvant
chemotherapy (taxane and/or anthracycline) followed by surgery, with a high residual
cancer burden (RCB-II or RCB-III) and received at least 1 cycle of adjC in PM or had
active surveillance (AS) in AC were evaluated. A descriptive comparison was made
between PM and AC. Recurrence free survival (RFS), overall survival (OS), and safety
profile were explored descriptively. Chi-Square test andMann-Whitney test were used
to assess categorical and continuous variables data, while Kaplan-Meier survival and
Cox-regression were used for time-to-event analyses.
Results: From 06/17 to 03/19, 21 patients received adjC in PM and from 04/02 to 03/19,
70 patients had AS in AC. Starting dose of capecitabine was 1000mg/m2 bid. Seven
patients (43.8%) completed 8 cycles, two (12.5%) received 6 cycles and for the remain-
ing patients therapy is ongoing. Themedian follow-up was 23months (range 1.9-36
months). At PM 76.2% of the patients were free from recurrence or death and 81%
were alive at 3 years. The mean RFS was better in the adjC group (mean 30.8 months vs
20.0 months HR: 0.23; p¼ 0.045). Mean OS was 29months in adjC group vs 28months
in AS (HR: 1.48; p¼ 0.610). Common adverse events were hand-foot syndrome,
fatigue, diarrhea, nausea and anemia. Dose reduction, delay to next chemotherapy cycle
or discontinuance of treatment were necessary in 13 (61.9%) patients.
Conclusions:Outcome of patients receiving adjC at PMwas better than those onAS in
AC, suggesting benefit from this treatment in a real-world setting. AdjC is an inexpensive,
widely available andwell tolerated oral chemotherapy and should be considered an option
for improvement of care even in public health systems of less developed countries.
Legal entity responsible for the study: The authors.
Funding: This work has been supported by a UICC Technical Fellowship.
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Background: Benefit derived from adjuvant chemotherapy (CT) is doubtful in a high
percentage of patients (pt) with hormone-receptor–positive HER2 negative early breast
cancer. The 21-gene recurrence-score (RS) assay Oncotype DX, provide prognostic and
predictive information. Results of the TAYLORx study have confirmed that most of
patients with negative node status and RS> 25 can avoid CT without increasing their
risk of relapse. However, pt< 50 years (y) and RS> 20 showed benefit with CT.
Methods: Aim: To analyse the impact of age using RS test to change the indication of
adjuvant CT and the relationship between different clinical pathological factors and the
RS value. We analysed 240 cases out of 251 RS test performed in the 3 ICO Centers dur-
ing 2017-2018.We compared the adjuvant treatment initially planned according to
institutional protocol with the treatment given after RS in the total cohort and in
pt< 50 y.We performed a logistical regression analysis of pathological factors and RS.
Results:CT was indicated in all pt before knowing the RS results. Only 46 pt (19%)
received CT after RS results. 14 out of 88 pt< 50 y received adjuvant CT (15%). 15 pt
<50 y had a RS between 21-25, only 5 of them received CT, because in most of them,
the RS was performed prior TAILORx results were published. Nowadays, all of these
15 pt would had received CT: 61/240 (25%). Clinical-pathological characteristics of the
series are summarized in the Table. Of the risk factors analysed, only Ki67>25
(<0.001) and PR 20% (0.01) showed a statistically significant relationship with a
higher probability of RS> 25 in a multivariate analysis.
Table: 209P
Age median (range) 53 (19-76)
<50 y 35.1%
50 y 64.9%
Tumor size median 15mm
Histological grade G1 23%
G2 69.7%
G3 4.4%
Progesterone receptor 20% 21%
>20% 78%
Ki67 median (p25-75) 20 (13,28)
14 27%
14-25 41%
>25% 31%
Nodal status pN0 57%
pN1mic 15%
pN1a 27%
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